Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'

This article was originally published in The Pink Sheet Daily

Executive Summary

Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.

Advertisement

Related Content

Oncology In 21st Century Cures: Heading Toward A Two-FDA Solution?
NIH Funding Component of 21st Century Cures May Get White House Boost
Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
FDA Oncology Advisory Committee Is Still Pazdur’s Center of Excellence
Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus
FDA's Combo Products Review Transformation Begins
FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?
Advertisement
UsernamePublicRestriction

Register